About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Posttraumatic Stress Disorder
Long Covid
Cocaine Intoxication
Migraine
Depression
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
COVID-19
Long COVID
Monkeypox
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
TNX-601 ER
TNX-1300
TNX-1900
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-102 SL
TNX-1850
TNX-801
Rare Disease
TNX-2900
Scientific Presentations
Expanded Access Policy
Clinical Trials
News & Events
Tonix in the News
Press Releases
Investor Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit
www.resilientstudy.com
or
www.clinicaltrials.gov
(NCT05273749).
IR Events
Investors
Investors
Overview
News & Events
Tonix in the News
Press Releases
IR Events
Email Alerts
Op-Eds
Presentations
Multimedia
Financial Info
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
A.G.P. Biotech Conference
Virtual
Nov 30 – Dec 1, 2022
